| Nov 1, 2025 | Artios Pharma | $120.0M Series D | Jake Simson, Nikola Trbovic | Andera Partners, EQT Life Sciences, Hakan Goker, M Ventures (Merck), Novartis Venture Fund, Pfizer Venture Investments, Invus, Janus Henderson Investors, LSP, Novartis, Omega Funds, Piper Heartland Healthcare Capital, Schroders Capital, Sofinnova Partners |
| Oct 1, 2025 | Affinia Therapeutics | $40.0M Series C | New Enterprise Associates | Atlas Venture, F-Prime Capital Partners, Ed Mathers, Alexandria Venture Investments, Eli Lilly and Company, F-Prime Capital, Google Ventures, Mass General Brigham Ventures, Perceptive Advisors |
| Sep 1, 2024 | Helaina | $45.0M Series B | Avidity Partners | Plum Alley Investments, Primary Venture Partners, Spark Capital, Hannah Bronfman, Scott Belsky, Tom Williams |
| Sep 1, 2024 | 858 Therapeutics | $50.0M Series B | Avidity Partners | Ali Behbahani, New Enterprise Associates, Versant Ventures |
| Apr 10, 2024 | TORL BioTherapeutics | $158.0M Series B | Rebecca Luse | Bristol Myers Squibb, Goldman Sachs, Perceptive Advisors, RA Capital Management, UC Investments, Vertex Ventures HC |
| Apr 1, 2024 | Endeavor BioMedicines | $130.0M Series C | AyurMaya, Karan Takhar | Atlas Venture, Hatteras Venture Partners, Omega Funds, RA Capital, Roche Venture Fund, abrdn, Ally Bridge Group, Eckuity Capital, Fidelity Management & Research Company, Invus, Longitude Capital, Perceptive Advisors, Piper Heartland Healthcare Capital, Silver Arch Bio, SymBiosis, T. Rowe Price Associates, Velosity Capital, Woodline Partners |
| Dec 12, 2023 | Calyxo | $50.0M Series D | Jacob Garfield | CRG, Questa Capital |
| Nov 1, 2023 | MBrace Therapeutics | $85.0M Series B | Carolyn Ng | Advanced Technology Ventures, Novo Ventures, RA Capital, Venrock, Bob Moore, Monal Mehta, Cowen Healthcare Investments |
| Aug 2, 2023 | CG Oncology | $105.0M Other Equity | Michael Rome, Giuliano Marostica | Acorn Bioventures, Ally Bridge Group, BVF Partners, Decheng Capital, Janus Henderson Investors, Longitude Capital, Malin Corporation, RA Capital Management |
| Jun 1, 2023 | Octave | $52.0M Series C | Jacob Garfield, Craig Cimini, Eric Snyder | American Express Ventures, Bessemer Venture Partners, Health Velocity Capital, sequel, Company Ventures, Felicis Ventures, Greycroft, Obvious Ventures |
| May 1, 2023 | Quanta Therapeutics | $51.0M Series D | Lei Meng | KohFounders, Carol Gallagher, Omega Funds, Sofinnova Investments, SV Health Investors, The Column Group, venBio, Venrock, Versant Ventures, Vida Ventures, AbbVie Ventures, BVF Partners, GC&H Investments, Longitude Capital, Surveyor Capital, WS Investment Company |
| Dec 2, 2022 | Upstream | $140.0M Series B | Coatue, Dragoneer Investment Group | Define Ventures |
| Dec 1, 2022 | Upstream Health | $140.0M Series B | Aaron Weiner, Eric Jones | Define Ventures |
| Oct 6, 2022 | Nested Therapeutics | $90.0M Series A | Goldman Sachs | Cowen Healthcare Investments, Foresite Capital, Section 32 |
| Aug 1, 2022 | Prellis Biologics | $35.0M Series C | Lei Meng, Michael Marks | American Express Ventures, Buckley Ventures, Celesta, Creative Ventures, Cultivation Capital, Electric Capital, FTW Ventures, Greylock, Helium-3 Ventures, iSelect Fund, Jude Gomila Rolling Fund, KAAN Ventures, Lightbank, LombardStreet Ventures, M34 Capital, Mayfield, Momenta Ventures, Plug & Play Ventures, Prime Movers Lab, Saga, SOSV, Starlight Ventures, Stray Dog Capital, Synthesis Capital, True Ventures, UpHonest Capital, Wilbur-Ellis [Cavallo], Alexander Gerko, Louis Beryl, Martin Añazco, Matt Bellamy, Mattia Astori, Michael Moritz, Paul Graham, Sahin Boydas, Sam Altman, Sue Xu, Khosla Ventures, Lucas Venture Group |
| Feb 1, 2022 | Endeavor BioMedicines | $100.0M Series B | Andrew Lam, Andrew Lam, Monal Mehta | Atlas Venture, Hatteras Venture Partners, Omega Funds, RA Capital, Roche Venture Fund, Patrick Enright, Perceptive Advisors, Piper Heartland Healthcare Capital, Revelation Partners, Tekla Capital Management, T. Rowe Price Associates |
| Jan 7, 2022 | AN2 Therapeutics | $80.0M Series B | RA Capital Management | BVF Partners, Hatteras Venture Partners, Monashee Investment Management, Surveyor Capital |
| Oct 1, 2021 | Elemy | $220.0M Series B | SoftBank | 9Yards Capital, Kevin Hartz, Accel, Acrew Capital, Adverb Ventures, Altair Capital Management, AME Cloud Ventures, Audrey Capital, Avalon Ventures, Benchstrength, Blitzscaling Ventures, Bond, Broadway Angels, C2 Investment, CapitalG, Coatue, Cota Capital, Craft Ventures, Daffy, Dragoneer Investment Group, Dream Machine, Flex Capital, Forerunner Ventures, FPV Fund, General Catalyst, Hardware Club, Helium-3 Ventures, Heretic Ventures, Incite Ventures, Liquid 2 Ventures, LOI Venture, Magnify Ventures, NFX, Pear VC, Polychain Capital, Quiet Capital, Redpoint Ventures, SciFi VC, Seven Seven Six, Sherpalo Ventures, SNR, Sound Ventures, South Park Commons, SV Angel, Timespan Ventures, Tribe Capital, Y Combinator, Aaron Levie, Aaron Patzer, Aston Motes, Charlie Cheever, Clara Shih, Dharmesh Shah, Doug Sleeter, Drew Houston, Eduardo Haber, Eric Ries, Hiten Shah, Jared Leto, Jeff Seibert, Jeremy Stoppelman, Josh Silverman, Justin Rosenstein, Justin Timberlake, Kris Duggan, Larry Augustin, Louis Beryl, Marco Zappacosta, Mark Pincus, Matt Bellamy, Matt Mickiewicz, Phil Libin, Sam Altman, Seth Sternberg, Stacy Brown-Philpot, Tien Tzuo, Tobias Lutke, Wayne Chang, Amity Ventures, Goodwater Capital, Metrodora Ventures, Premji Invest, Whale Rock Capital |
| Aug 3, 2021 | Zentera Therapeutics | $75.0M Series B | OrbiMed, Tybourne Capital Management | Casdin Capital, Farallon Capital Management, Lilly Asia Ventures, Logos Capital, Perceptive Advisors, Redmile Group, Surveyor Capital, Viking Global Investors |
| Aug 1, 2021 | GentiBio | $160.0M Series A | Andy Tran | Matrix Capital Management Company, JDRF T1D Fund, Novartis, OrbiMed, RA Capital Management, Seattle Children's Research Institute |
| Jul 27, 2021 | Artios | $152.0M Series C | Michelle Doig, Chen Yu | Andera Partners, Mark Chin, dRx Capital, Invus, LSP, M Ventures, Piper Heartland Healthcare Capital, RTW Investments, Schroders Capital, Sofinnova Partners, Soleus Capital, SV Health Investors, Tetragon Financial Group |
| Jul 1, 2021 | Artios Pharma | $150.0M Series C | Michelle Doig, Chen Yu | Andera Partners, EQT Life Sciences, Hakan Goker, M Ventures (Merck), Novartis Venture Fund, Pfizer Venture Investments, Arix Bioscience, CaaS Capital Management, Deep Track Capital, Invus, LSP, Novartis, Piper Heartland Healthcare Capital, RTW Investments, Schroders Capital, Sofinnova Partners, Soleus Capital, SV Health Investors, Tetragon Financial Group |
| Jul 1, 2021 | Exo | $220.0M Series C | Zach Scheiner | RA Capital, BlackRock, Pura Vida Investments, Sands Capital |
| May 20, 2021 | Biotheryx | $92.0M Series E | Farallon Capital Management | Alexandria Venture Investments, Deep Track Capital, Irving Investors, Janus Henderson Investors, Lumira Ventures, Point72, Rock Springs Capital, Surveyor Capital, Tekla Capital Management, Wedbush Healthcare Partners |
| May 1, 2021 | Affinia Therapeutics | $110.0M Series B | Caroline Stout, Farallon Capital Management | Atlas Venture, F-Prime Capital Partners, Ed Mathers, New Enterprise Associates, Casdin Capital, F-Prime Capital, Google Ventures, Lonza, Mass General Brigham Ventures, Octagon Capital, Perceptive Advisors, RA Capital Management, TCGX, Woodline Partners |
